Abeona Therapeutics’ (ABEO) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a report issued on Thursday morning,Benzinga reports. HC Wainwright currently has a $20.00 target price on the biopharmaceutical company’s stock.

Several other equities analysts have also recently weighed in on ABEO. Stifel Nicolaus set a $17.00 price target on Abeona Therapeutics in a report on Tuesday. Weiss Ratings reiterated a “sell (d+)” rating on shares of Abeona Therapeutics in a research report on Wednesday, January 21st. Finally, Oppenheimer reissued an “outperform” rating on shares of Abeona Therapeutics in a report on Monday, March 9th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $19.00.

Abeona Therapeutics Stock Down 2.0%

ABEO opened at $4.45 on Thursday. The company has a quick ratio of 9.53, a current ratio of 6.93 and a debt-to-equity ratio of 0.05. The firm has a 50 day moving average price of $5.07 and a 200-day moving average price of $5.19. Abeona Therapeutics has a twelve month low of $3.93 and a twelve month high of $7.54. The stock has a market capitalization of $253.87 million, a price-to-earnings ratio of 4.32 and a beta of 1.13.

Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Tuesday, March 17th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.01. The company had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $5.65 million. Equities research analysts forecast that Abeona Therapeutics will post -1.16 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Christine Berni Silverstein sold 20,070 shares of Abeona Therapeutics stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $5.09, for a total transaction of $102,156.30. Following the transaction, the director owned 137,722 shares in the company, valued at $701,004.98. This trade represents a 12.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Eric Crombez sold 16,284 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $5.09, for a total transaction of $82,885.56. Following the sale, the director directly owned 63,456 shares of the company’s stock, valued at approximately $322,991.04. The trade was a 20.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 209,605 shares of company stock valued at $1,101,300. 6.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Abeona Therapeutics

Hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd increased its position in Abeona Therapeutics by 25.4% in the fourth quarter. XTX Topco Ltd now owns 49,338 shares of the biopharmaceutical company’s stock worth $260,000 after buying an additional 9,979 shares in the last quarter. Tang Capital Management LLC purchased a new position in shares of Abeona Therapeutics during the 4th quarter valued at about $5,270,000. Balyasny Asset Management L.P. bought a new position in shares of Abeona Therapeutics during the 4th quarter valued at approximately $3,118,000. J. Goldman & Co LP bought a new position in shares of Abeona Therapeutics during the 4th quarter valued at approximately $2,102,000. Finally, AQR Capital Management LLC increased its holdings in Abeona Therapeutics by 240.7% in the 4th quarter. AQR Capital Management LLC now owns 114,520 shares of the biopharmaceutical company’s stock worth $604,000 after acquiring an additional 80,908 shares in the last quarter. Institutional investors own 80.56% of the company’s stock.

More Abeona Therapeutics News

Here are the key news stories impacting Abeona Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and a $20.00 price target on ABEO, highlighting upside in the firm’s longer-term view despite near-term headwinds. HC Wainwright Reiterates Buy
• Positive Sentiment: Abeona announced tightened shareholder meeting and governance rules (Third Amended and Restated provisions), which can reduce activist/governance uncertainty and may be viewed favorably by longer-term investors. Governance Update
• Neutral Sentiment: Market consensus coverage shows a “Moderate Buy” view from brokerages — supportive but not unanimous; useful context for sentiment but not a catalyst by itself. Consensus Rating
• Neutral Sentiment: Reported short-interest data showed effectively zero reported short interest in the most recent snapshot, so short-covering is unlikely to be driving intraday moves. (Internal data summary)
• Negative Sentiment: HC Wainwright materially lowered near-term EPS forecasts across 2026 quarters and reduced FY2026 from about ($0.97) to ($1.14), signaling weaker near-term profitability/revenue expectations — a key driver of the stock’s downward pressure. Analyst Estimate Cuts
• Negative Sentiment: Multiple quarterly EPS cuts for 2026 and early‑2027 (Q1–Q3 2026 and Q2 2026 revisions were notable) increase uncertainty about near-term operating performance and could delay any valuation rerating despite the $20 target. Estimate Details

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.